🇺🇸 FDA
Patent

US 11866418

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

granted A61KA61K9/50A61P

Quick answer

US patent 11866418 (Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K9/50, A61P, A61P13/12, A61P25/28